IMBRUVICA® Is an Oral, Once-Daily WM Medication That Works Differently Than Chemotherapy
- IMBRUVICA® blocks a protein in B cells called Bruton’s tyrosine kinase, or BTK . BTK signaling is needed for abnormal B cells to multiply and survive1
- By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs1,2
Because of how IMBRUVICA® works, it may cause side effects.1
A relationship between how IMBRUVICA® works and why it helps to treat certain diseases has not been clearly identified.
References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. de Rooij MFM, Kuli A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594. 3. Medline Plus. Isolated growth hormone deficiency. Accessed August 23, 2022. https://ghr.nlm.nih.gov/condition/isolated-growth-hormone-deficiency#genes